An in silico approach to discovering novel inhibitors of human sirtuin type 2

Journal of Medicinal Chemistry

Volumn 47, Issue 25, 2004, Pages 6292-6298

  Tervo, Anu J ^a,b   Kyrylenko, Sergiy ^a   Niskanen, Päivi ^a   Salminen, Antero ^a,c   Leppänen, Jukka ^a   Nyrönen, Tommi H ^b   Järvinen, Tomi ^a   Poso, Antti ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b IT Center for Science   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[1 (2 HYDROXYNAPHTHALEN 1 YL)METHYLIDENE]AMINO] N (1 PHENYLETHYL)BENZAMIDE; 8,9 DIHYDROXYBENZO[4,5]FURO[3,2 C]CHROMEN 6 ONE; ALPHA TUBULIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; PHENOL DERIVATIVE; PROTEIN INHIBITOR; SIRTINOL; SIRTUIN; SIRTUIN 2 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; COMPUTER MODEL; DEACETYLATION; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IC 50; IN VITRO STUDY; INHIBITION KINETICS; MICROTUBULE ASSEMBLY; MITOSIS; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION;

ANTHRAQUINONES; BENZENE DERIVATIVES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DATABASES, FACTUAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHENOLS; PYRIDINES; SIRTUINS; TRIAZOLES;

EID: 9744284968     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049933m     Document Type: Article

References (46)

1. Khochbin, S.; Verdel, A.; Lemercier, C.; Seigneurin-Berny, D. Functional significance of histone deacetylase diversity. Curr. Opin. Genet. Dev. 2001, 11, 162-166.
2. Imai, S.; Armstrong, C. M.; Kaeberlein, M.; Guarente, L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000, 403, 795-800.
3. Landry, J.; Sutton, A.; Tafrov, S. T.; Heller, R. C.; Stebbins, J.; et al. The silencing protein SIR2 and its homologues are NAD-dependent protein deacetylases. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 5807-5811.
4. Chang, J. H.; Kim, H. C.; Hwang, K. Y.; Lee, J. W.; Jackson, S. P.; et al. Structural basis for the NAD-dependent deacetylase mechanism of Sir2. J. Biol. Chem. 2002, 277, 34489-34498.
5. Sauve, A. A.; Schramm, V. L. Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry 2003, 42, 9249-9256.
6. Landry, J.; Slama, J. T.; Sternglanz, R. Role of NAD(+) in the deacetylase activity of the SIR2-like proteins. Biochem. Biophys. Res. Commun. 2000, 278, 685-690.
7. Sauve, A. A.; Celic, I.; Avalos, J.; Deng, H.; Boeke, J. D.; et al. Chemistry of gene silencing: The mechanism of NAD+-dependent deacetylation reactions. Biochemistry 2001, 40, 15456-15463.
8. Gasser, S. M.; Cockell, M. M. The molecular biology of the SIR proteins. Gene 2001, 279, 1-16.
9. Tanner, K. G.; Landry, J.; Sternglanz, R.; Denu, J. M. Silent information regulator 2 family of NAD-dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 14178-14182.
10. Shore, D. The Sir2 protein family: A novel deacetylase for gene silencing and more. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 14030-14032.
11. Gottschling, D. E. Gene silencing: Two faces of SIR2. Curr. Biol. 2000, 10, R708-711.
12. Lin, S. J.; Defossez, P. A.; Guarente, L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces ceremsiae. Science 2000, 289, 2126-2128.
13. Guarente, L. SIR2 and aging-the exception that proves the rule. Trends. Genet. 2001, 17, 391-392.
14. Guarente, L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 2000, 14, 1021-1026.
15. Hiratsuka, M.; Inoue, T.; Toda, T.; Kimura, N.; Shirayoshi, Y.; et al. Proteomics-based identification of differentially expressed genes in human gliomas: Down-regulation of SIRT2 gene. Biochem. Biophys. Res. Commun. 2003, 309, 558-566.
16. Krämer, O. H.; Göttlicher, M.; Heinzel, T. Histone deacetylase as a therapeutic target. Trends. Endocrinol. Metab. 2001, 12, 294-300.
17. Frye, R. A. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem. Biophys. Res. Commun. 1999, 260, 273-279.
18. Frye, R. A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 2000, 273, 793-798.
19. North, B. J.; Marshall, B. L.; Borra, M. T.; Denu, J. M.; Verdin, E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell. 2003, 11, 437-444.
20. Dryden, S. C.; Nahhas, F. A.; Nowak, J. E.; Goustin, A. S.; Tainsky, M. A. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol. Cell. Biol. 2003, 23, 3173-3185.
21. Finnin, M. S.; Donigian, J. R.; Pavletich, N. P. Structure of the histone deacetylase SIRT2. Nat. Struct. Biol. 2001, 8, 621-625.
22. Bellamacina, C. R. The nicotinamide dinucleotide binding motif: A comparison of nucleotide binding proteins. FASEB J. 1996, 10, 1257-1269.
23. Bedalov, A.; Gatbonton, T.; Irvine, W. P.; Gottschling, D. E.; Simon, J. A. Identification of a small molecule inhibitor of Sir2p. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 15113-15118.
24. Grozinger, C. M.; Chao, E. D.; Blackwell, H. E.; Moazed, D.; Schreiber, S. L. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 2001, 276, 38837-38843.
25. Grozinger, C. M.; Schreiber, S. L. Deacetylase enzymes: Biological functions and the use of small-molecule inhibitors. Chem. Biol. 2002, 9, 3-16.
26. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
27. Kleywegt, G. J.; Jones, T. A. Phi/psi-chology: Ramachandran revisited. Structure 1996, 4, 1395-1400.
28. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857.
29. Maybridge Chemicals Database; Maybridge Chemicals Co. Ltd.: Trevillet, Tintangel, Cornwall PL34 OHW, England.
30. Vaziri, H.; Dessain, S. K.; Ng Eaton, E.; Imai, S. I.; Frye, R. A.; et al. hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107, 149-159.
31. Hempen, B.; Brion, J. P. Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 1996, 55, 964-972.
32. Zhang, Y.; Li, N.; Caron, C.; Matthias, G.; Hess, D.; et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO. J. 2003, 22, 1168-1179.
33. Sybyl 6.8 and 6.8.1; Tripos Inc.: St. Louis, MO.
34. Herman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; et al. The Protein Data Bank. Nucleic Acid Res. 2000, 28, 235-242.
35. Quanta 2000 molecular modeling package; Accelrys Inc.: 200 Wheeler Road South Tower 2nd Floor Burlington, MA 01803-5501.
36. Lindahl, E.; Hess, B.; van der Spoel, D. GROMACS 3.0: A package for molecular simulation and trajectory analysis. J. Mol. Mod. 2001, 7, 306-317.
37. van Gunsteren, W. F.; Billeter, S. R.; Eising, A. A.; Hünenberger, P. H.; Krüger, P.; et al. Biomolecular Simulation: The GROMOS96 manual and user guide.; Hochschulverlag AG an der ETH Zürich: Zürich, Switzerland, 1996.
38. van der Spoel, D.; van Buuren, A. R.; Apol, E.; Meulenhoff, P. J.; Tieleman, D. P.; et al. Gromacs User Manual version 3.0: Nijenborgh 4, 9747 AG, Groningen, The Netherlands, 2001.
39. Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; Hermans, J. Interaction models for water in relation to protein hydration. Intermolecular Forces; D. Reidel Publishing Co.: Dordrecht, 1981; pp 331-342.
40. Berendsen, H. J. C.; Postma, J. P. M.; DiNola, A.; Haak, J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 1984, 81, 3684-3690.
41. Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An N-log(N) method for Ewald sums in large systems. J. Chem. Phys. 1993, 98, 10089-10092.
42. Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; et al. A smooth particle mesh Ewald potential. J. Chem. Phys. 1995, 103, 8577-8592.
43. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
44. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Delivery Rev. 1997, 23, 4-25.
45. Cruciani, G.; Pastor, M.; Guba, W. VolSurf: A new tool for the pharmacokinetic optimization of lead compounds. Eur. J. Pharm. Sci. 2000, 11 Suppl 2, 29-39.
46. Cruciani, G.; Crivori, P.; Carrupt, P.-A.; Testa, B. Molecular fields in quantitative structure-permeation relationships: The VolSurf approach. J. Mol. Struct. THEOCHEM 2000, 503, 17-30.